Clinical Trial Update: Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial studying alirocumab in patients with heterozygous familial hypercholesterolemia undergoing LDL apheresis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Heterozygous Familial Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2020-05-01